secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001213900-22-071704
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron reports Q3 2022 net loss of $5.2M; completes Phase 2a Alzheimer's enrollment
--------------------------------------------------------------------------------

- Net loss of $5.2M ($0.25 per share) vs $4.9M in Q3 2021; revenue up to $0.3M from $0.2M.
- Completed enrollment in Phase 2a Lomecel-B trial for mild Alzheimer's Disease; topline results expected 2024.
- FDA granted Fast Track Designation for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS).
- Cash and short-term investments of $22.3M; expected runway into first half 2024.
- R&D expenses increased 45% to $2.9M; G&A decreased 31% to $2.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/0001213900-22-071704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/ea168423-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer